Zheng Quan Shi Bao Wang·2025-11-06 02:04Core Insights - The company, Innovent Biologics, announced that its newly developed BCL2 inhibitor Mesutoclax and BTK inhibitor Orelabrutinib have over 20 research results selected for the 67th American Society of Hematology (ASH) Annual Meeting, including 2 oral presentations and 20 poster displays [1][2][4]. Group 1: Mesutoclax Research Highlights - Mesutoclax has three studies selected for the ASH meeting, with one oral presentation focused on its efficacy in treating relapsed/refractory mantle cell lymphoma (MCL) showing high remission rates even in patients previously resistant to BTK inhibitors [1]. - The oral presentation titled "Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients" is scheduled for December 8, 2025 [1]. - Two poster presentations include studies on Mesutoclax's activity in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and myeloid malignancies, demonstrating encouraging efficacy and safety [2][3]. Group 2: Orelabrutinib Research Highlights - Orelabrutinib has over 20 studies selected for the ASH meeting, including one oral presentation and multiple poster displays covering various diseases such as marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL) [4][5]. - The oral presentation titled "Mid-treatment CSF ctdna and MYD88 clearance outperform PET-CT in predicting response and survival to orelabrutinib-based induction in newly diagnosed PCNSL" is scheduled for December 6, 2025 [4]. - Key poster presentations include studies on Orelabrutinib combined with other therapies for treating marginal zone lymphoma and DLBCL, indicating promising results [5][6][7]. Group 3: Company Overview - Innovent Biologics is a commercial-stage biopharmaceutical company focused on developing innovative drugs for oncology and autoimmune diseases, with multiple products in commercialization, clinical, and preclinical stages [10]. - The company has branches in major cities including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States [10].